Previous 10 | Next 10 |
home / stock / biib / biib articles
On Wednesday, Biogen Inc (NASDAQ:BIIB) reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The...
Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semi...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
The FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly and Company...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Comp...
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
New data advances understanding of new approaches to treating Alzheimer's disease Research on disease progression could help inform future c...
NEW YORK, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigati...
Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...